Pairing New Cancer Drugs With Older Ones Bolsters Roche Profit
- Schwan says combination strategy is way of future in cancer
- Swiss drugmaker to raise dividend, sees sales growing
Roche CEO Confident Business Will Succeed Despite Turmoil
This article is for subscribers only.
Roche Holding AG said combining tumor medicines for extra potency, a strategy that helped spur first-half earnings by reviving sales of older drugs like Herceptin, is the way of the future in cancer.
The drugmaker’s core earnings, which exclude some items, rose 7 percent to 7.74 Swiss francs per share from 7.22 francs a year earlier, the Basel, Switzerland-based company said in a statement Thursday. That exceeded the 7.65-franc estimate of nine analysts surveyed by Bloomberg.